Mesa Laboratories Inc /Co/ (MLAB) — SEC Filings
Mesa Laboratories Inc /Co/ (MLAB) — 24 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 9 8-K, 6 10-Q, 5 SC 13G/A.
View Mesa Laboratories Inc /Co/ on SEC EDGAR
Overview
Mesa Laboratories Inc /Co/ (MLAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Mesa Laboratories, Inc. reported a mixed financial performance for the three and six months ended September 30, 2025. For the three months, revenues increased by 5.02% to $60.737 million from $57.833 million in the prior year, driven by growth in Biopharmaceutical Development and Calibration Solutio
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 20 neutral, 2 mixed. The dominant filing sentiment for Mesa Laboratories Inc /Co/ is neutral.
Filing Type Overview
Mesa Laboratories Inc /Co/ (MLAB) has filed 6 10-Q, 9 8-K, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of MLAB's 19 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $60.737M |
| Net Income | $2.476M |
| EPS | $0.45 |
| Cash Position | $20.422M |
| Operating Margin | 7.78% |
| Total Assets | $430.351M |
| Total Debt | $251.883M |
Key Executives
- CODM
- Non-PEO NEO
- PEO
- John Sakys
- Gary Owens
- Brian Archbold
- Michael Jones
Industry Context
Mesa Laboratories operates in the specialized fields of calibration services and biopharmaceutical development support. The calibration market is characterized by a need for accuracy, compliance with standards, and specialized equipment. The biopharmaceutical development sector requires services that support drug discovery, development, and manufacturing, often involving complex regulatory pathways and a demand for high-quality, reliable testing and validation.
Top Tags
institutional-ownership (4) · amendment (4) · corporate-governance (3) · Industrial Instruments (3) · earnings (3) · acquisition (3) · Financial Performance (2) · shareholder-vote (2) · debt (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenues (3 months) | $60.737M | Increased from $57.833M in prior year, a 5.02% increase |
| Net Income (3 months) | $2.476M | Decreased from $3.428M in prior year, a 27.79% decrease |
| Revenues (6 months) | $120.280M | Increased from $116.003M in prior year, a 3.69% increase |
| Net Income (6 months) | $7.218M | Increased from $6.816M in prior year, a 5.89% increase |
| Cash and Cash Equivalents | $20.422M | Decreased from $27.321M at March 31, 2025 |
| Revolving Line of Credit | $106.000M | Increased from $10.000M at March 31, 2025 |
| GKE Acquisition Holdback | $9.555M | Payment made during the six months ended September 30, 2025 |
| Diluted EPS (3 months) | $0.45 | Decreased from $0.63 in prior year |
| Diluted EPS (6 months) | $1.30 | Increased from $1.25 in prior year |
| Net Cash Used in Financing Activities | $16.310M | For the six months ended September 30, 2025 |
| Commission File Number | 0-11740 | Identifies the company's SEC filing history |
| I.R.S. Employer Identification No. | 84-0872291 | Company's tax identification number |
| Net Loss | $1,190 | Net loss for the quarter ended June 30, 2025, compared to $1,186 in the prior-year quarter. |
| Total Revenues | $27,827 | Total revenues for the quarter ended June 30, 2025, up from $26,421 in the prior-year quarter. |
| Revenue Growth | 5.3% | Percentage increase in total revenues from the prior-year quarter to the current quarter. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Mesa Laboratories Inc. for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Mesa Laboratories Inc /Co/ (MLAB)?
Mesa Laboratories Inc /Co/ has 24 recent SEC filings from Jan 2024 to Nov 2025, including 9 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MLAB filings?
Across 24 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 20 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Mesa Laboratories Inc /Co/ SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mesa Laboratories Inc /Co/ (MLAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mesa Laboratories Inc /Co/?
Key financial highlights from Mesa Laboratories Inc /Co/'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MLAB?
The investment thesis for MLAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mesa Laboratories Inc /Co/?
Key executives identified across Mesa Laboratories Inc /Co/'s filings include CODM, Non-PEO NEO, PEO, John Sakys, Gary Owens and 2 others.
What are the main risk factors for Mesa Laboratories Inc /Co/ stock?
Of MLAB's 19 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Mesa Laboratories Inc /Co/?
Recent forward-looking statements from Mesa Laboratories Inc /Co/ include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Mesa Laboratories Inc. for the foreseeable future.","en.